TY - JOUR
AU1 - McPherson, Timothy
AU2 - Kolling, William M
AB - Commentary Am J Health-Syst Pharm. 2023;80:1271-1274 The United States Pharmacopeia for the preparation. Extended in-use (USP) defines stability as “the extent to stability of diluted parenteral prod- timothy mcPherson, PhD, Southern which a product retains, within speci- ucts, stability of drugs diluted in dif- Illinois University Edwardsville School of Pharmacy, Edwardsville, IL, USA fied limits, and throughout its period of ferent intravenous (IV) fluids or stored William m. Kolling, PhD, Southern Illinois storage and use (i.e., its shelf-life), the at different temperatures, and stability University Edwardsville School of Pharmacy, same properties and characteristics that of nonsterile extemporaneous oral so- Edwardsville, IL, USA it possessed at the time of its manufac- lutions or suspension preparations are ture.” The 3 relevant types of stability examples of this type of study. Address correspondence to Dr. for compounded drug preparations 2. A parenteral compatibility study in- McPherson (tmcpher@siue.edu). are chemical, physical, and microbio- volves the mixing of 2 or more par- logical. The beyond-use date (BUD) enteral drug solutions to determine Keywords: assay validation, data is used instead of a compounded drug if they may be administered simul- accuracy, drug stability, nephelometry, parenteral compatibility, pH 2 preparation’s shelf-life. taneously to a patient. Compatibility measurement, precision 
TI - Stability and compatibility study guidelines for AJHP
JF - American Journal of Health-System Pharmacy
DO - 10.1093/ajhp/zxad132
DA - 2023-06-06
UR - https://www.deepdyve.com/lp/oxford-university-press/stability-and-compatibility-study-guidelines-for-ajhp-uPe83ZqwYC
SP - 1271
EP - 1274
VL - 80
IS - 18
DP - DeepDyve
ER -